The safety of ORLADEYO® is supported by data from patients across 2 clinical studies1
In APeX-2 (part 1), the most commona treatment-emergent adverse reactions were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease (GERD)1
a≥10% and higher than placebo.1
bIncludes abdominal pain, abdominal discomfort, abdominal tenderness, and upper abdominal pain.1
cIncludes diarrhea and frequent bowel movements.1
- No patients in the ORLADEYO 150 mg dose group and 1 patient in the ORLADEYO 110 mg dose group discontinued treatment due to a gastrointestinal (GI) adverse reaction in APeX-2 part 11
- Findings from the open-label, long-term safety study, APeX-S (interim safety population, n=227), support the data observed in APeX-2 (part 1)1
- No new types of side effects were seen in those who continued ORLADEYO for 96 weeks3
- One patient receiving ORLADEYO 150 mg discontinued treatment due to a GI abdominal adverse reaction in APeX-2 part 33
GI adverse reactions generally occurred early after initiation of treatment, became less frequent with time, and typically self-resolved1
Abbreviation: TEAE, treatment-emergent adverse event.
- If GI reactions persist, a reduced dosage of 110 mg once daily with food may be considered1
Setting expectations with patients regarding possible adverse reactions can help ensure a strong start.5
Set treatment expectations
Download the flashcard to help your patients start strong on ORLADEYO.